Loading the section…

IBIO: financial statements from SEC — TradeAlmanac

IBIO

iBio, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	31/03/2025	31/12/2024	30/09/2024
Revenue	—	0	100,000	0	200,000	0
Research and development	3M	4M	4M	2M	2M	1M
Selling, general and administrative	5M	5M	3M	3M	3M	3M
Operating expenses	8M	9M	6M	5M	5M	4M
Operating income	−8M	−9M	−6M	−5M	−4M	−4M
Net income	−8M	−9M	−6M	−5M	−4M	−4M
Earnings per share	−0.06	−0.09	−0.11	−0.49	−0.48	−0.46
Earnings per share, diluted	−0.06	−0.09	−0.11	−0.49	−0.48	−0.46
Weighted average shares	120M	99M	53M	10M	9M	9M
Weighted average shares, diluted	120M	99M	53M	10M	9M	9M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	48M	29M	28M	9M	5M	7M	11M	14M
Receivables	—	—

Cash flow

Metric	30/09/2025	30/09/2024
Operating cash flow	−6M	−4M
Depreciation and amortisation	123,000	120,000
Share-based compensation	323,000	415,000
Capital expenditure	32,000	0
Investing cash flow	−21M	713,000
Financing cash flow	47M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator